Opinion on Biotech in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Genentech/Roche: another boost for blockbuster Avastin

Roche has announced that its Genentech unit has submitted two supplemental Biologics License Applications to the FDA for Avastin in the first-line treatment of metastatic HER-2-negative breast cancer. The regulator will most likely approve Avastin for these indications on the basis of progression-free survival extension results from Phase III clinical trial data.

Published By Datamonitor
18 Nov 2009
CommentWire
CommentWire

Top pharmaceutical and biotech companies face slowdown in sales growth over 2008-14

A Datamonitor report has identified that the leading pharmaceutical and biotech companies face a major slowdown in sales growth out to 2014, primarily a result of the imminent patent expiries facing many blockbusters and the subsequent threat from generics. Prescription sales are expected to rise at a compound annual growth rate of just 1.2% over 2008-14, compared to a historical rate of 10.5%.

Published By Datamonitor
01 Mar 2010
Expert View
Expert View

Dendreon: landmark cancer vaccine approval but high costs may hinder uptake

Having been approved by the FDA in castration-resistant prostate cancer, Dendreon's Provenge represents the first therapeutic cancer vaccine to reach the market. This is a significant step forward: the current standard of care is Taxotere-based chemotherapy, which is associated with significant toxicity. However, it remains to be seen how frequently Provenge is used.

Published By Datamonitor
30 Apr 2010
Expert View
Expert View

Amgen promotes novel offering at World Congress on Osteoporosis

The 2010 International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis in May was the most important meeting of the year in the osteoporosis arena. While no new groundbreaking data for the drug were revealed, Amgen used the congress to promote its novel monoclonal antibody denosumab.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Prolia: useful, but not quite revolutionary

Having received approval in both the US and Europe within the space of a few days, Datamonitor expects Amgen's osteoporosis antibody Prolia to achieve sales of over $850m across the seven major markets by 2019. However, despite its first-in-class status, Prolia is unlikely to revolutionize the current treatment algorithm, as existing unmet needs remain.

Published By Datamonitor
03 Jun 2010
Expert View
Expert View

AUA 2010: vaccine data and potential new treatments drive interest in prostate cancer

This year's meeting of the American Urological Association saw several major pharmaceutical players presenting new data and discussing potential new pathways for disease treatment. Among the areas of focus was prostate cancer, with Dendreon presenting new data for its groundbreaking vaccine Provenge and Amgen highlighting the potential of Prolia in the treatment of this disease.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

AUA 2010: encouraging new drugs in benign prostatic hyperplasia but challenges remain

Datamonitor attended this year's meeting of the American Urological Association, at which data were presented for two promising new candidates developed for the treatment of benign prostatic hyperplasia. Specifically, Watson Pharmaceuticals outlined the differentiators for its new treatment Rapaflo, while Nymox used the meeting to present new data for its pipeline drug NX-1207.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

ATS 2010: developments in IPF and cystic fibrosis

The FDA's recent refusal of Esbriet and the publication of new guidelines for the treatment of idiopathic pulmonary fibrosis drove considerable interest in this disease at the 2010 meeting of the American Thoracic Society. Furthermore, the approval of the first new inhaled antibiotic for cystic fibrosis in over a decade brought renewed focus on this rare but extremely debilitating disease.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

ATS 2010: shift in asthma guidelines highlights focus on personalized medicine

Datamonitor attended this year's meeting of the American Thoracic Society in New Orleans. The 2010 conference was defined not only by the latest clinical trial data, but by new guidelines and an emerging discussion of the role of personalized treatment. Conclusions were also presented from the ISAAC study, highlighting some surprising global prevalence trends.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

APA 2010: limited data highlight unmet needs in bipolar disorder

Several leading drug makers presented new data in bipolar disorder at this year's meeting of the American Psychiatric Association. Despite Cephalon's Nuvigil showing promise as an adjunct, modest data for antipsychotics from Merck & Co and Pfizer served only to highlight the remaining unmet needs in the treatment of this disease.

Published By Datamonitor
08 Jun 2010

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.